Cumulative data did not suggest an increased risk of preterm birth, major congenital anomalies, or other adverse outcomes with ocrelizumab in utero exposure and were consistent with epidemiological ...

Multiple sclerosis (MS) patients treated with ocrelizumab (Ocrevus) had a higher risk of infections over time than other MS patients, a real-world cohort study showed. The risk for serious infection ...

Review the side-effects of Ocrelizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . Continuous administration of ocrelizumab in clinical trials and its broader use in real-world settings exhibited ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...

Peter L. Salgo, MD: You’ve already established, you have already made it very clear, that early treatment is important. Preventing as much damage as possible is important. And now I know you wanted to ...

GOTHENBURG, Sweden--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (NASDAQ:BIIB) today announced 24-week results 1 from a phase II study ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

The appraisal committee considered evidence submitted by Roche and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. Other than ...